Veracyte, Inc. (VCYT) , a leading name in cancer diagnostics, is set to showcase compelling data from three studies demonstrating the capabilities of its Afirma GRID (Genomic Resource for Intelligent Discovery) tool at ENDO 2024 from Jun 1-4. These findings promise to enhance the personalization of thyroid cancer treatment, marking a significant step forward in the molecular testing landscape. By enhancing the depth and accuracy of molecular testing, Veracyte's Afirma GRID tool is poised to play a crucial r ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...

Financial Data and Key Metrics Changes - The company reported first-quarter revenue of $96.8 million, a 17% increase compared to the prior year period, driven by a 25% growth in the testing business [17][31] - Total testing volume reached approximately 33,500 tests, reflecting a 16% increase year-over-year [31] - Non-GAAP gross margin was 68%, down approximately 70 basis points year-over-year, while testing ASP was approximately $2,900 [34][32] Business Line Data and Key Metrics Changes - Decipher Prostate tests delivered 16,500 units, achieving a new quarterly volume record, with growth from both new and existing providers [5][17] - Afirma reported approximately 14,000 test results, with a 14% revenue growth compared to the prior year [21] - Biopharmaceutical and other revenue was $3 million, down 51% year-over-year due to overall spending constraints across the industry [33] Market Data and Key Metrics Changes - The American Cancer Society estimates approximately 300,000 new cases of prostate cancer in 2024, indicating a growing market for Decipher [11] - The company aims for 80% penetration in both Prostate and Fibroid Cancer Molecular Tests, indicating a significant market opportunity [9] Company Strategy and Development Direction - The company is focused on global expansion through a robust IVD strategy and solving new cancer challenges via its diagnostics platform [25][58] - The acquisition of C2i genomics is expected to enhance the company's offerings in Minimal Residual Disease (MRD) testing [12][29] - The company plans to launch its first MRD test for muscle-invasive bladder cancer in the first half of 2026 [58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Decipher, citing strong market penetration and the impact of updated NCCN guidelines [39][49] - The company raised its total revenue guidance for 2024 to $402 million to $410 million, reflecting an improved outlook for its testing business [36] - Management acknowledged challenges in enrollment for the NIGHTINGALE trial but remains optimistic about the market potential for the nasal swab test [27][42] Other Important Information - The company downsized commercial support for the InvisioTest but will continue to offer it to patients facing interstitial lung disease [26] - The updated NCCN guidelines for Decipher Prostate received a level 1b evidence rating, the highest for gene expression tests for prostate cancer [19] Q&A Session Summary Question: Growth rate for Decipher and market penetration - Management indicated that Decipher's growth is driven by market penetration, share gains, and overall market growth, with a 30% year-over-year volume increase and a 36% revenue growth [68] Question: Enrollment slowdown in NIGHTINGALE trial - Management noted that enrollment challenges are typical in large multi-site trials and are not indicative of market interest [42][43] Question: Biopharma-related activities and revenue potential - Management acknowledged a pipeline of new customers and projects in biopharma, indicating potential for future growth despite current constraints [77] Question: Demand for Afirma GRID and clinician interest - Management reported significant interest from academic settings and rural communities, indicating a positive trend for Afirma [81] Question: Medicare reimbursement impact on Afirma - Management clarified that while TERT testing provides some benefit, it is not expected to significantly uplift ASP due to limited patient selection [83] Question: Development strategy for MRD testing - Management expressed confidence in launching the MRD test for muscle-invasive bladder cancer by early 2026, emphasizing control over the necessary assessments [97]

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q1 2024 Business and Financial Presentation | | | | | | | | | | | | May 7, 2024 | | | | | Forward-looking statements and non-GAAP information Total Revenue by Quarter1 $72.4 $81.7 $82.0 $90.4 $90.3 $3.9 $4.0 $4.0 $3.7 $3.5 $6.1 $4.6 $4.1 $4.1 $3.0 $82.4 $90.3 $90.1 $98.2 $96.8 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Testi ...

"We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to further penetrate these markets by expanding our clinical evidence, and, for Decipher, securing enhanced status in guidelines while also achieving a key commercial reimbursement milestone," said Marc Stapley, Veracyte's chief executive officer. "We also expanded our capabilities into minimal residual disease (MRD) testing by completing our acquisition of C2i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-5455398 (State or Other Jurisdiction of Incor ...

Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Dustin Scaringe - William Blair Matt Sykes - Goldman Sachs Puneet Souda - Leerink Partners Operator Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2023 Financial R ...

| --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q4 2023 Business and Financial Presentation | | | | | | | | February 22, 2024 | | | | | | | This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Puneet Souda – Leerink Sung Ji Nam – Scotiabank Mason Carrico – Stephens Inc Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2023 Financial Results Webcast. At this time all participants are in a listen-only mod ...